Document is current
Any future updates will be listed below
-
Authors
Chen, Pingyu
Fu, Chang
Shen, Lin
Fei, Zhengyang
Luo, Mengjie
Chen, Yanqiu
Li, Hongchao
- License Information
-
More Information
Article History
Received: 7 April 2023
Accepted: 23 May 2024
First Online: 29 May 2024
Declarations
:
: The protocol has received approval from the Institutional Review Board/Independent Ethics Committee, including, but not limited to the Medical Ethics Committee of Beijing Cancer Hospital, the EC of Fudan University Shanghai Cancer Center, and the Medical Ethics Committee of Henan Cancer Hospital, as elaborated in the Supplementary Material. The full Protocol is available with BeiGene BGB-A317-302 CLINICAL STUDY PROTOCOL Protocol Amendment 4.0 20 March 2020. The study was carried out in accordance with the International Conference on Harmonisation Good Clinical Practice Guideline, the principles of the Declaration of Helsinki, and local laws and regulations. All patients provided written informed consent before participation. <b>Consent for publication</b>.
: Not applicable.
: The authors declare no competing interests.
